- IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to...
- Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) formed in October by combination of Virios Therapeutics, Inc. and Pharmagesic (Holdings) Inc., 100% parent company of Wex Pharmaceuticals, Inc. (the...
ATLANTA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced...
ATLANTA, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced...
Strategic financing by an affiliate of CK Life Sciences Int’l., (Holdings) Inc., results in working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron®...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0803 | -3.08846153846 | 2.6 | 2.7009 | 2.37 | 19153 | 2.45383339 | CS |
4 | -1.8103 | -41.8083140878 | 4.33 | 4.7067 | 1.62 | 79341 | 2.67896784 | CS |
12 | -1.0303 | -29.0225352113 | 3.55 | 5.29 | 1.62 | 112477 | 3.61113657 | CS |
26 | -1.0303 | -29.0225352113 | 3.55 | 5.29 | 1.62 | 112477 | 3.61113657 | CS |
52 | -1.0303 | -29.0225352113 | 3.55 | 5.29 | 1.62 | 112477 | 3.61113657 | CS |
156 | -1.0303 | -29.0225352113 | 3.55 | 5.29 | 1.62 | 112477 | 3.61113657 | CS |
260 | -1.0303 | -29.0225352113 | 3.55 | 5.29 | 1.62 | 112477 | 3.61113657 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約